Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02603224 | Safety, Tolerability and Pharmacokinetic Study of MRG-201 in Healthy Volunteers | PHASE1 | COMPLETED | 54 | — | — | Nov 1, 2015 | Apr 1, 2017 | Jul 6, 2017 | 1 | Canada |
| Arm | Type | Description |
|---|---|---|
| MRG-201 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| MRG-201 | DRUG | Intradermal injection of single ascending doses and multiple ascending doses in healthy volunteers. |
| Placebo | DRUG | Intradermal injection of placebo at a second site in healthy volunteers. Each subject will serve as their own control. |
Inclusion Criteria: * Healthy males between 18 and 45 years of age inclusive * Body Mass Index (BMI) 18-35 kg/m\^2 inclusive * Must have 2 regions on the lower back/upper buttocks free of striae, scars, tattoos or other skin pathologies * If engaged in sexual relations with a female of child-bearin...